Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials-Reference-Cited by-同舟云学术

Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials

Published:2024-09 Issue: Volume: Page:
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Vale Claire,Godolphin Peter J,Fisher David,Horby Peter W,Kosiborod Mikhail N,Hochman Judith S,Webster Katie,Higgins Julian P T,Althouse Andrew D,Berwanger Otavio,Furtado Remo H M,Gasparyan Samvel B,Haynes Richard,Koch Gary G,Landray Martin,Leifer Eric,Marshall John,Murthy Srinivas,Neal Matthew D,Staplin Natalie,Diaz Janet,Sterne Jonathan A C,Shankar-Hari Manu

Publisher

Elsevier BV

Reference38 articles.

1. Extrapulmonary manifestations of COVID-19;Gupta;Nat Med,2020

2. A guide to immunotherapy for COVID-19;van de Veerdonk;Nat Med,2022

3. Empagliflozin in patients with chronic kidney disease;Herrington;N Engl J Med,2023

4. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis;McGuire;JAMA Cardiol,2021

5. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial;Kosiborod;Lancet Diabetes Endocrinol,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial;The Lancet Diabetes & Endocrinology;2024-09